Resverlogix R&D per Employee

What does Resverlogix do? Resverlogix Corp is a biopharmaceutical company based in Canada that specializes in the research and development of innovative therapies for cardiovascular diseases. It was founded in 2001 by Dr. Donald J. McCaffrey and has been listed on the Toronto Stock Exchange since 2006. The company focuses on the development of synthetic molecules with the same potential as Resveratrol, a natural compound found in red grapes and wine, for the treatment of cardiovascular diseases. Resverlogix Corp follows an innovative business model that involves identifying disease-causing factors and developing targeted molecules to influence them, with the goal of developing effective therapies for patients with cardiovascular diseases. The company specializes in the development of therapeutic agents for atherosclerosis and diabetic nephropathy, and currently has two main products in clinical development: Apabetalone for the treatment of atherosclerosis and BAC25 for diabetic nephropathy. Apabetalone acts directly on the genome of cells and influences the gene expression of proteins relevant to the development of atherosclerosis, while BAC25 targets glucose and lipid metabolism in the kidney to slow down or prevent the development of diabetic nephropathy. Overall, Resverlogix Corp is a biopharmaceutical company focused on innovative therapies for cardiovascular diseases, with a business model based on identifying disease-causing factors and developing synthetic molecules to target them. Resverlogix is one of the most popular companies on Eulerpool.